Connect with us


The biotech industry embraces crowdfunding: Capital Cell moves 14 million in investment in 2020

The crowdfunding platform Capital Cell specialized in the biomedical sector has contributed to the closing of a total of fourteen financing rounds. The largest financing round was the $2.42 million (€2 million) round closed by Ability Pharma last November. Investors participated with amounts ranging from $605 (€500) to more than $121,000 (€100,000).



Crowdfunding is gaining ground in the biotech sector. The Capital Cell platform, which specializes in raising investment for companies in the healthcare sector, moved $17 million (€14 million) in 2020, contributing to the closure of fourteen rounds of financing, compared to $12 million (€10 million) in 2019, as confirmed by Daniel Oliver, founder of Capital Cell. 

Read more details about the raising of capital in the health sector and find other important business headlines with our companion app Born2Invest.

Only six rounds valued at $4.66 million (€3.85 million) were closed in 2018

In 2017, the platform moved $2.06 million (€1.7 million) in three different campaigns, according to Capital Cell. Within the investments completed during the Covid-19 year, the weight of individual contributions played a particularly relevant role. According to data provided by the company itself, pure crowdfunding injected more than ten million euros into the companies that presented themselves on the platform.  The average size per funding round at Capital Cell was $1.17 million (€966,100) in 2020 In 2020, the average size per funding round was €966,100, the average investment rate per week amounted to $257,400 (€212,600) and the average investment per person was $2,280 (€1,880). 

Capital Cell also explained that 79.8% of investments came from men, while the remaining 20.1% came from women. Investment from outside Spain only accounts for 4% of the total. In terms of domestic investment, 66.6% comes from Catalonia, 11.9% from Madrid, while the remaining 4.2% is from the Basque Country. The largest financing round was the $2.42 million (€2 million) round closed by Ability Pharma last November. The round, in which investors participated with amounts ranging from $605 (€500) to more than $121,000 (€100,000), will enable the Catalan biotech to continue developing anti-tumor treatments. 

The operation was led by an industrial partner and a business angel, both from the pharmaceutical sector, and between them they invested around $423,000 (€350,000). The names were not disclosed. The raising of these two million euros came after the Catalan company received a grant of 1.6 million euros from the U.S. Food and Drug Administration (FDA) through the National Institute of Health (NIH).   

Ability Pharma received $1.94 million (€1.6 million) from the U.S. Drug Enforcement Agency through the National Institute of Health Another company that recently closed a round of funding through Capital Cell is Methinks for more than $1.21 million (€1 million). The startup leverages the capabilities of artificial intelligence in the field of medical image analysis to solve one of today’s biggest medical problems: stroke. This investment round will allow Methinks to launch its product to the market and complete licensing agreements. Methinks is an artificial intelligence system capable of analyzing scanner images of patients who have suffered a stroke and determining the exact type of vascular accident, even if the image is a simple scan or even if the doctor responsible is not a stroke specialist.


(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.